随着时间的推移,与多发性硬化症相关的疾病修饰疗法使用和卫生资源利用:加拿大阿尔伯塔省的一项回顾性队列研究
Erin F Balcom1, Penelope Smyth1, Mahesh Kate1
1University of Alberta, Faculty of Medicine and Dentistry, Department of Medicine, Edmonton, Alberta T6G 2R3, Canada.
Journal of the neurological sciences
|February 9, 2024
概括
多发性硬化症 (MS) 患病率在阿尔伯塔州上升,发病率下降. 用疾病修饰疗法 (DMT) 治疗和门诊访问增加,而住院治疗减少,反映出MS护理的发展.
科学领域:
- 神经学 神经学
- 流行病学 流行病学
- 医疗保健服务研究 医疗服务研究
背景情况:
- 了解多发性硬化症 (MS) 的负担和治疗演变至关重要.
- 评估疾病修饰疗法 (DMT) 和医疗保健资源利用率至关重要.
研究的目的:
- 为了估计阿尔伯塔省在2003-2019年间的MS患病率和发病率.
- 描述1998-2019年间多发性硬化症患者 (pwMS) 中的DMT和医疗保健资源利用情况.
主要方法:
- 使用行政数据进行回顾性,基于人口的研究.
- 分析MS流行,发病率,DMT使用和医疗保健资源利用情况.
主要成果:
- 多发性硬化症的患病率增加;发生率下降.
- 德米使用量上升,随着对新疗法的转变.
- 门诊访问增加;急诊和住院率下降.
结论:
- 在全球范围内,阿尔伯塔州的MS病率很高.
- 增加的DMT和门诊护理,以及急性护理的减少,表明MS管理正在发展.
- 新的疗法和疾病负担的变化正在重塑MS护理.
相关概念视频
Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...


